Small molecule · Antagonist of C-C chemokine receptor type 4 (CCR4) · developed by RAPT Therapeutics, Inc., a member of the GSK plc group of companies
RPT193 is an antagonist of the chemokine receptor CCR4. It inhibits CCR4-mediated chemotaxis toward the ligands CCL22 and CCL17. It is being studied in asthma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05935332 | Phase 2 | Asthma | Terminated | GSK |
| NCT06087978 | Phase 1 | Healthy Male Subjects | Completed | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AsthmaHealthy Male Subjects
Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →